Accession Number:



Mesenchymal Stem Cell Therapy for Traumatic Brain Injury

Descriptive Note:

Technical Report,15 Mar 2018,14 Mar 2019

Corporate Author:

US Army Institute of Surgical Research Fort Sam Houston United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Traumatic brain injury TBI is a significant cause of death and disability in military and civilian populations. Cell therapy with mesenchymal stem cells MSCs shows promise for TBI. Because not all MSCs are equivalent, further work is needed to define optimal MSC products to minimize risk and maximize benefit. Here we proposed to establish a panel of assays to evaluate safety and potency of cell therapy products prior to administration. Assay results were used to select MSCs with different profiles for preclinical testing in rats. The maximal tolerated dose of MSCs will be determined in both uninjured and injured rats, and the distribution and retention of labeled cells following intravenous administration will be determined. MSC administration will be tested in rats subjected to TBI, and the impact of the cell therapy will be measured using a combination of histological, functional and behavioral testing.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: